Indometacin farnesil
Systematic (IUPAC) name | |
---|---|
(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetate | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | To indometacin |
Biological half-life | 1.5 hours |
Excretion | Renal |
Identifiers | |
CAS Number | 85801-02-1 |
ATC code | None |
PubChem | CID 5282183 |
ChemSpider | 4445378 |
Chemical data | |
Formula | C34H40ClNO4 |
Molar mass | 562.14 g/mol |
| |
| |
(verify) |
Indometacin farnesil (INN) is a prodrug of the non-steroidal anti-inflammatory drug indometacin, designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indometacin with farnesol. Indometacin farnesil was first approved in Japan in 1991, and is available in Japan and Indonesia, under the trade names Infree and Dialon, respectively.
External links
|
This article is issued from Wikipedia - version of the Tuesday, April 19, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.